Iressa Casts Shadow Over Zarnestra Advisory Committee Review

The rejection of J&J's Zarnestra by an FDA advisory committee suggests that the failure of Iressa to demonstrate clinical benefit will have consequences for the next generation of oncology NDAs

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet